Observation study of Trastuzumab for HER2 positive advanced or recurrent gastric cancer - Observation study of Trastuzumab for HER2 positive advanced or recurrent gastric cancer(KSCC1105)

Kyushu Study group of Clinical Cancer0 个研究点目标入组 50 人开始时间: 2012年2月8日最近更新: 2023年10月17日

适应症

试验速览

阶段: 4 期
状态: 已完成
发起方
入组人数: 50

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

ASCO-GI 2017 Trastuzumab beyond first progression in cases of HER2-positive advanced gastric or gastro-esophageal junction cancer: Initial results from KSCC1105, a trastuzumab observational cohort study. Akitaka Makiyama, Mototsugu Shimokawa, Tomomi Kashiwada, Ikuo Takahashi, Yasunori Emi, Tetsuya Kusumoto, Kazuharu Yamamoto, Hiroshi Ishikawa, Yuji Negoro, Eiji Oki, Hiroshi Saeki, Yoshihiro Kakeji, Hideo Baba,Yoshihiko Maehara, Kyushu Study Group of Clinical Cancer (KSCC)

研究设计

研究类型: Observational

入排标准

年龄范围: ot applicable 至 ot applicable（—）
性别: All

入选标准

未提供

排除标准

•Other than inclusion criteria

研究者

发起方

Kyushu Study group of Clinical Cancer

相似试验

已完成

2 期

Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric CancerStomach NeoplasmsNeoplasms MetastasisERBB2 Gene Amplification

NCT02004769Sun Yat-sen University67

已完成

2 期

A phase II clinical trial (KSCC/HGCSG/CCOG/PerSeUS1501B) examining oxaliplatin + S-1 + trastuzumab for treatment of HER2-positive advanced/recurrent gastric cancer previously untreated with chemotherapyGastric Cancer

JPRN-UMIN000017552Kyushu Study group of Clinical Cancer40

已完成

2 期

Phase II Neoadjuvant Trial of Trastuzumab in Combination With Dose-Dense ABI-007 (Abraxane™)Breast Cancer

NCT00503750Emory University27

已完成

不适用

Trastuzumab Based Therapy in HER2 Positive AGCGastric Adenocarcinoma

NCT03024450Shanghai Zhongshan Hospital98

招募中

2 期

A phase2 study of trastumab and TS-1 for HER2-positive advanced gastric cancerGastric Cancer

JPRN-UMIN000006115Shimane University Hospital20